Reata Pharmaceuticals Inc buy melinda
Start price
23.07.18
/
50%
?59.89
Target price
25.07.18
€63.14
Performance (%)
12.39%
End price
25.07.18
€67.32
Summary
This prediction ended on 25.07.18 with a price of €67.32. The BUY prediction by melinda finished with a performance of 12.39%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Reata Pharmaceuticals Inc | - | - | - | - |
| iShares Core DAX® | 4.094% | 4.888% | 17.421% | 22.413% |
| iShares Nasdaq 100 | 1.424% | -0.445% | 37.618% | 58.203% |
| iShares Nikkei 225® | -1.572% | -4.911% | 12.951% | 7.961% |
| iShares S&P 500 | 1.822% | 0.776% | 29.182% | 49.914% |
Comments by melinda for this prediction
In the thread Reata Pharmaceuticals Inc diskutieren
SecteurRecherche biotechnologique et médicale Agenda 13/08 Publication de résultats
Provides pharmaceutical products for treatment of inflammatory diseases and cancer
Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products.
Its lead product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.
The company was founded by J. Warren Huff on September 1, 2002 and is headquartered in Irving, TX.
Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products.
Its lead product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.
The company was founded by J. Warren Huff on September 1, 2002 and is headquartered in Irving, TX.
Nombre d'employés : 93 personnes.
(Vom Mitglied beendet)
Stopped prediction by melinda for Reata Pharmaceuticals Inc
Reata Pharmaceuticals Inc
Start price
Target price
Perf. (%)
?84.56
03.04.19
03.04.19
€92.00
04.11.19
04.11.19
0.00%
04.11.19
04.11.19
Reata Pharmaceuticals Inc
Start price
Target price
Perf. (%)
?88.32
27.02.19
27.02.19
€90.20
04.03.19
04.03.19
2.32%
04.03.19
04.03.19
Reata Pharmaceuticals Inc
Start price
Target price
Perf. (%)
?29.52
21.10.17
21.10.17
€31.57
06.12.17
06.12.17
-30.35%
06.12.17
06.12.17
Reata Pharmaceuticals Inc
Start price
Target price
Perf. (%)
?32.73
21.10.17
21.10.17
€35.00
06.12.17
06.12.17
-30.35%
06.12.17
06.12.17